MX2020004678A - Uso de profarmacos de riluzol para tratar ataxias. - Google Patents
Uso de profarmacos de riluzol para tratar ataxias.Info
- Publication number
- MX2020004678A MX2020004678A MX2020004678A MX2020004678A MX2020004678A MX 2020004678 A MX2020004678 A MX 2020004678A MX 2020004678 A MX2020004678 A MX 2020004678A MX 2020004678 A MX2020004678 A MX 2020004678A MX 2020004678 A MX2020004678 A MX 2020004678A
- Authority
- MX
- Mexico
- Prior art keywords
- prodrugs
- riluzol
- ataxias
- treat
- riluzole
- Prior art date
Links
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 title abstract 3
- 239000000651 prodrug Substances 0.000 title abstract 3
- 229940002612 prodrug Drugs 0.000 title abstract 3
- 206010003591 Ataxia Diseases 0.000 title abstract 2
- 229960004181 riluzole Drugs 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- YBZSGIWIPOUSHY-UHFFFAOYSA-N troriluzole Chemical compound NCC(=O)NCC(N(CC(NC=1SC2=C(N=1)C=CC(=C2)OC(F)(F)F)=O)C)=O YBZSGIWIPOUSHY-UHFFFAOYSA-N 0.000 abstract 1
- 229940121629 troriluzole Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762584856P | 2017-11-12 | 2017-11-12 | |
| US201862717948P | 2018-08-13 | 2018-08-13 | |
| PCT/US2018/060232 WO2019094851A1 (en) | 2017-11-12 | 2018-11-11 | Use of riluzole prodrugs to treat ataxias |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004678A true MX2020004678A (es) | 2020-08-13 |
Family
ID=66438598
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004678A MX2020004678A (es) | 2017-11-12 | 2018-11-11 | Uso de profarmacos de riluzol para tratar ataxias. |
| MX2023012640A MX2023012640A (es) | 2017-11-12 | 2020-07-13 | Uso de profarmacos de riluzol para tratar ataxias. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012640A MX2023012640A (es) | 2017-11-12 | 2020-07-13 | Uso de profarmacos de riluzol para tratar ataxias. |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20210023061A1 (enExample) |
| EP (2) | EP4483956B1 (enExample) |
| JP (2) | JP7352542B2 (enExample) |
| KR (2) | KR20250034521A (enExample) |
| CN (1) | CN112292127A (enExample) |
| AU (1) | AU2018364749C1 (enExample) |
| BR (1) | BR112020009173A2 (enExample) |
| CA (1) | CA3082096A1 (enExample) |
| DK (1) | DK3706739T3 (enExample) |
| ES (1) | ES2996892T3 (enExample) |
| FI (1) | FI3706739T3 (enExample) |
| HR (1) | HRP20241675T1 (enExample) |
| HU (1) | HUE070302T2 (enExample) |
| IL (1) | IL274532B2 (enExample) |
| LT (1) | LT3706739T (enExample) |
| MD (1) | MD3706739T2 (enExample) |
| MX (2) | MX2020004678A (enExample) |
| PH (1) | PH12020550583A1 (enExample) |
| PL (1) | PL3706739T3 (enExample) |
| PT (1) | PT3706739T (enExample) |
| RS (1) | RS66277B1 (enExample) |
| SG (1) | SG11202004332XA (enExample) |
| SI (1) | SI3706739T1 (enExample) |
| SM (1) | SMT202500022T1 (enExample) |
| WO (1) | WO2019094851A1 (enExample) |
| ZA (1) | ZA202002626B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12295942B2 (en) | 2015-03-03 | 2025-05-13 | Biohaven Therapeutics Ltd. | Riluzole prodrugs and their use |
| LT3265448T (lt) | 2015-03-03 | 2022-04-11 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzolo provaistai ir jų naudojimas |
| US12029731B2 (en) | 2016-08-10 | 2024-07-09 | Biohaven Therapeutics Ltd. | Acyl benzo[d]thiazol-2-amine and their methods of use |
| WO2022155564A1 (en) * | 2021-01-18 | 2022-07-21 | Biohaven Therapeutics Ltd. | Use of riluzole prodrugs to treat alzheimer's disease |
| WO2023081860A1 (en) * | 2021-11-04 | 2023-05-11 | Skyhawk Therapeutics, Inc. | Triazine amino derivatives for treating sca3 |
| KR20250020409A (ko) * | 2022-05-23 | 2025-02-11 | 바이오하벤 테라퓨틱스 리미티드 | 척수소뇌성 운동실조증을 치료하는 방법 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| EP0804170B1 (en) | 1993-07-09 | 2001-11-14 | R.P. Scherer Corporation | Method for making freeze dried drug dosage forms |
| US5457895A (en) | 1993-10-01 | 1995-10-17 | R. P. Scherer Corporation | Method of identifying freeze-dried dosage forms |
| US5837287A (en) | 1994-10-28 | 1998-11-17 | R P Scherer Corporation | Process for preparing solid pharmaceutical dosage forms |
| EP0973507B1 (en) | 1997-02-20 | 2009-01-21 | Massachussets Institute of Technology | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
| DE69834255T2 (de) | 1997-07-25 | 2006-09-28 | Alpex Pharma S.A. | Verfahren zur herstellung eines granulates, geeignet zur herstellung schnell-freisetzender, im mund löslicher tabletten |
| FR2774592B1 (fr) * | 1998-02-06 | 2000-03-17 | Rhone Poulenc Rorer Sa | Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet |
| SK288117B6 (sk) | 1998-11-20 | 2013-09-03 | Skyepharma Canada Inc. | Rapidly dispersing solid dry therapeutic dosage form |
| GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| US6284270B1 (en) | 1999-08-04 | 2001-09-04 | Drugtech Corporation | Means for creating a mass having structural integrity |
| US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| US6814978B2 (en) | 2000-12-29 | 2004-11-09 | Mcneil-Ppc, Inc. | Process for preparing a soft tablet |
| US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
| ATE371442T1 (de) | 2001-10-12 | 2007-09-15 | Elan Pharma Int Ltd | Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung |
| CA2476250C (en) | 2002-02-13 | 2010-08-03 | Michael K. Weibel | Drug dose-form and method of manufacture |
| DK1477166T3 (da) * | 2003-04-28 | 2006-12-11 | Biofrontera Bioscience Gmbh | Anvendelse af riluzoler kombineret med egnede hjælpe- og tilsætningsstoffer til behandling af sygdomme, som er kendetegnet ved en hyperproliferation af keratinocytter, navnlig neurodermitis og psoriasis |
| US7282217B1 (en) | 2003-08-29 | 2007-10-16 | Kv Pharmaceutical Company | Rapidly disintegrable tablets |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| BRPI0620578A2 (pt) | 2005-12-27 | 2011-12-06 | Jubilant Organosys Ltd | composição farmacêutica que dissolve na boca e processo para o preparo da mesma |
| WO2009002084A2 (en) | 2007-06-27 | 2008-12-31 | Hanmi Pharm. Co., Ltd. | Method for preparing rapidly disintegrating formulation for oral administration and apparatus for preparing and packing the same |
| JP2011516489A (ja) * | 2008-03-31 | 2011-05-26 | ユニバーシティ・オブ・サウス・フロリダ | 疾患誘発性運動失調症および非運動失調性平衡異常の治療法 |
| US8849441B2 (en) | 2008-10-31 | 2014-09-30 | The Invention Science Fund I, Llc | Systems, devices, and methods for making or administering frozen particles |
| US8731842B2 (en) | 2008-10-31 | 2014-05-20 | The Invention Science Fund I, Llc | Compositions and methods for biological remodeling with frozen particle compositions |
| US8313768B2 (en) | 2009-09-24 | 2012-11-20 | Mcneil-Ppc, Inc. | Manufacture of tablet having immediate release region and sustained release region |
| LT3265448T (lt) * | 2015-03-03 | 2022-04-11 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzolo provaistai ir jų naudojimas |
-
2018
- 2018-11-11 PT PT188767792T patent/PT3706739T/pt unknown
- 2018-11-11 SG SG11202004332XA patent/SG11202004332XA/en unknown
- 2018-11-11 PL PL18876779.2T patent/PL3706739T3/pl unknown
- 2018-11-11 CN CN201880073828.6A patent/CN112292127A/zh active Pending
- 2018-11-11 BR BR112020009173-1A patent/BR112020009173A2/pt unknown
- 2018-11-11 HU HUE18876779A patent/HUE070302T2/hu unknown
- 2018-11-11 MD MDE20200953T patent/MD3706739T2/ro unknown
- 2018-11-11 WO PCT/US2018/060232 patent/WO2019094851A1/en not_active Ceased
- 2018-11-11 EP EP24199849.1A patent/EP4483956B1/en active Active
- 2018-11-11 DK DK18876779.2T patent/DK3706739T3/da active
- 2018-11-11 KR KR1020257006278A patent/KR20250034521A/ko active Pending
- 2018-11-11 SM SM20250022T patent/SMT202500022T1/it unknown
- 2018-11-11 IL IL274532A patent/IL274532B2/en unknown
- 2018-11-11 LT LTEPPCT/US2018/060232T patent/LT3706739T/lt unknown
- 2018-11-11 MX MX2020004678A patent/MX2020004678A/es unknown
- 2018-11-11 HR HRP20241675TT patent/HRP20241675T1/hr unknown
- 2018-11-11 KR KR1020207016775A patent/KR20200103658A/ko not_active Ceased
- 2018-11-11 FI FIEP18876779.2T patent/FI3706739T3/fi active
- 2018-11-11 US US16/762,165 patent/US20210023061A1/en active Pending
- 2018-11-11 RS RS20241371A patent/RS66277B1/sr unknown
- 2018-11-11 CA CA3082096A patent/CA3082096A1/en active Pending
- 2018-11-11 ES ES18876779T patent/ES2996892T3/es active Active
- 2018-11-11 JP JP2020526149A patent/JP7352542B2/ja active Active
- 2018-11-11 EP EP18876779.2A patent/EP3706739B1/en active Active
- 2018-11-11 AU AU2018364749A patent/AU2018364749C1/en active Active
- 2018-11-11 SI SI201831180T patent/SI3706739T1/sl unknown
-
2020
- 2020-05-08 PH PH12020550583A patent/PH12020550583A1/en unknown
- 2020-05-11 ZA ZA2020/02626A patent/ZA202002626B/en unknown
- 2020-07-13 MX MX2023012640A patent/MX2023012640A/es unknown
-
2023
- 2023-07-17 US US18/353,840 patent/US12102618B2/en active Active
- 2023-07-17 US US18/353,850 patent/US20230355592A1/en active Pending
- 2023-09-15 JP JP2023149803A patent/JP2023175823A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022010241A2 (es) | Inhibidores de sos1 | |
| MX2023012640A (es) | Uso de profarmacos de riluzol para tratar ataxias. | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| MX2020011104A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| UY37272A (es) | Piridinas sustituidas con heteroarilo y métodos de uso | |
| CR20190318A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| UY37435A (es) | Pirrolidinas sustituidas y métodos para usarlas | |
| MX2016014547A (es) | Compuestos para tratar atrofia muscular espinal. | |
| MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
| CL2016002346A1 (es) | Composiciones para modular la expresión de ataxina 2 | |
| BR112016023558A2 (pt) | compostos úteis como imunomoduladores | |
| MX2016011038A (es) | Compuestos para el tratamiento de trastornos mediados por complemento. | |
| UY36702A (es) | Piridinas sustituidas y métodos de uso | |
| UY35916A (es) | Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio | |
| MX381069B (es) | Profármacos de carbidopa y l-dopa y métodos de uso. | |
| CO2017003838A2 (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| BR112019021867A2 (pt) | Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil | |
| UY36677A (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| BR112016028845A2 (pt) | composto, composição farmacêutica e uso de um composto | |
| MX2016004530A (es) | Rapamicina para el tratamiento de linfangioleiomiomatosis. | |
| DOP2017000107A (es) | Diamino-quinoleina 2,4 sustituida como nuevos agentes anticancerigenos | |
| MX2017005283A (es) | Nuevos derivados de pirazol en calidad de inhibidores de la cinasa inductora de nf-kb (nik). | |
| CL2021000329A1 (es) | Compuestos útiles en terapia del vih | |
| SV2017005466A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 |